266 related articles for article (PubMed ID: 29243101)
1. Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy.
Neuner JM; Shi Y; Kong AL; Kamaraju S; Smith EC; Smallwood AJ; Laud PW; Charlson JA
J Cancer Surviv; 2018 Apr; 12(2):268-275. PubMed ID: 29243101
[TBL] [Abstract][Full Text] [Related]
2. Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients.
Neuner JM; Yen TW; Sparapani RA; Laud PW; Nattinger AB
Osteoporos Int; 2011 Nov; 22(11):2847-55. PubMed ID: 21170643
[TBL] [Abstract][Full Text] [Related]
3. Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer.
Koopal C; Janssen-Heijnen ML; van de Wouw AJ; van den Bergh JP
Breast; 2015 Apr; 24(2):153-8. PubMed ID: 25618224
[TBL] [Abstract][Full Text] [Related]
4. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.
Ligibel JA; James O'Malley A; Fisher M; Daniel GW; Winer EP; Keating NL
Breast Cancer Res Treat; 2012 Jan; 131(2):589-97. PubMed ID: 21881937
[TBL] [Abstract][Full Text] [Related]
5. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
Bromley SE; Matthews A; Smeeth L; Stanway S; Bhaskaran K
J Cancer Surviv; 2019 Aug; 13(4):632-640. PubMed ID: 31321612
[TBL] [Abstract][Full Text] [Related]
6. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
Abdel-Qadir H; Amir E; Fischer HD; Fu L; Austin PC; Harvey PJ; Rochon PA; Lee DS; Anderson GM
Eur J Cancer; 2016 Nov; 68():11-21. PubMed ID: 27693889
[TBL] [Abstract][Full Text] [Related]
7. Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.
Kamaraju S; Shi Y; Smith E; Nattinger AB; Laud P; Neuner J
Clin Cardiol; 2019 Jan; 42(1):93-100. PubMed ID: 30443921
[TBL] [Abstract][Full Text] [Related]
8. Bayesian synthesis using prior information on fracture risk from randomized trials to analyze post-market data.
John-Baptiste A; Becker T; Fung K; Lipscombe LL; Austin PC; Anderson GM
J Clin Epidemiol; 2018 Sep; 101():79-86. PubMed ID: 29879465
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen use reduces the risk of osteoporotic fractures in women with breast cancer in Asia: a nationwide population-based cohort study.
Tzeng HE; Muo CH; Chen HT; Hwang WL; Hsu HC; Tsai CH
BMC Musculoskelet Disord; 2015 May; 16():123. PubMed ID: 25989902
[TBL] [Abstract][Full Text] [Related]
10. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors.
Matthews AA; Peacock Hinton S; Stanway S; Lyon AR; Smeeth L; Lund JL; Bhaskaran K
Heart; 2021 Aug; 107(16):1327-1335. PubMed ID: 33177117
[TBL] [Abstract][Full Text] [Related]
11. The impact of treatment compliance on fracture risk in women with breast cancer treated with aromatase inhibitors in the United Kingdom.
Schmidt N; Jacob L; Coleman R; Kostev K; Hadji P
Breast Cancer Res Treat; 2016 Jan; 155(1):151-7. PubMed ID: 26687384
[TBL] [Abstract][Full Text] [Related]
12. Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
Leslie WD; Morin SN; Lix LM; Niraula S; McCloskey EV; Johansson H; Harvey NC; Kanis JA
Oncologist; 2019 Nov; 24(11):1432-1438. PubMed ID: 31292269
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen use correlates with increased risk of hip fractures in older women with breast cancer: A case-control study in Taiwan.
Hung SC; Liao KF; Hung HC; Lin CL; Lee PC; Hung SJ; Lai SW
Geriatr Gerontol Int; 2019 Jan; 19(1):56-60. PubMed ID: 30511361
[TBL] [Abstract][Full Text] [Related]
14. Emerging bone health issues in women with breast cancer in Hawai'i.
Carney JF; Davis J
Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
[TBL] [Abstract][Full Text] [Related]
15. Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.
Mincey BA; Duh MS; Thomas SK; Moyneur E; Marynchencko M; Boyce SP; Mallett D; Perez EA
Clin Breast Cancer; 2006 Jun; 7(2):127-32. PubMed ID: 16800971
[TBL] [Abstract][Full Text] [Related]
16. Age-related differences in persistence in women with breast cancer treated with tamoxifen or aromatase inhibitors in Germany.
Jacob L; Hadji P; Kostev K
J Geriatr Oncol; 2016 May; 7(3):169-75. PubMed ID: 27091510
[TBL] [Abstract][Full Text] [Related]
17. Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
Santen RJ
J Clin Endocrinol Metab; 2011 Feb; 96(2):308-19. PubMed ID: 21147884
[TBL] [Abstract][Full Text] [Related]
18. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Gibson LJ; Dawson C; Lawrence DH; Bliss JM
Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
[TBL] [Abstract][Full Text] [Related]
19. Effect of tamoxifen and aromatase inhibitors on the risk of fractures in women with breast cancer.
Vestergaard P; Rejnmark L; Mosekilde L
Calcif Tissue Int; 2008 May; 82(5):334-40. PubMed ID: 18463912
[TBL] [Abstract][Full Text] [Related]
20. Hormonal therapy for breast cancer and diabetes incidence among postmenopausal women.
Santorelli ML; Hirshfield KM; Steinberg MB; Rhoads GG; Lin Y; Demissie K
Ann Epidemiol; 2016 Jun; 26(6):436-40. PubMed ID: 27157863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]